Stage
No active trials
Next date
None yet
Trials
0 active
9 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TR group: The first period,the subjects will be administrated with SHR-1459 in new formulation, then conduct blood collection within 48h; 7 days washout; The second period,the subjects will be administrated with SHR-1459 in old formulation, then conduct blood collection within 48h. RT group: The first period,the subjects will be administrated with SHR-1459 in old formulation, then conduct…”In the company’s words, NCT04395053 on ClinicalTrials.gov
- Tested for
- Neuromyelitis Optica Spectrum Disorders, Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma, Primary Membranous Nephropathy, B-cell Tumors, Mature B Cell Neoplasms, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Main trialPhase 2
- “This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs.”In the company’s words, NCT04670770 on ClinicalTrials.gov
- Other names
- TG-1701 · No other intervention · BTK inhibitor
Other drugs for Neuromyelitis Optica Spectrum Disorders
- EculizumabAlexion Pharmaceuticals, Inc. · Phase 3
- SatralizumabRoche · Phase 3
- B001Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- RavulizumabAlexion Pharmaceuticals, Inc. · Phase 3
- DivozilimabBiocad · Phase 3
- MIL62Beijing Mabworks Biotech Co., Ltd. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 15 Aug 2022 | An Open Label Study of the Effects of SHR1459 in NMOSDs Patients | |
| Phase 2Unknown | Apr 2023 | SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma | |
| Phase 2Unknown | 28 Aug 2023 | Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy | |
| Phase 1Completed | 11 Jul 2020 | A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers | |
| Phase 1Completed | 14 Dec 2020 | Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin) | |
| Phase 1Unknown | 5 Jul 2022 | Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers | |
| Phase 1Completed | 2 Dec 2022 | A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects | |
| Phase 1Unknown | 30 Dec 2023 | Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor | |
| Phase 1Terminated | 21 May 2024 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026